Neurocrine Biosciences (NBIX) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $80. H.C. Wainwright advised their investors in a research report released on Jun 29, 2016.
On the company’s financial health, Neurocrine Biosciences reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.29. The company had revenue of $15.00 million for the quarter, compared to analysts expectations of $15.43 million. The company’s revenue was down -24.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.01 EPS.
Neurocrine Biosciences closed down -1.49 points or -3.44% at $41.79 with 13,28,904 shares getting traded on Monday. Post opening the session at $43.21, the shares hit an intraday low of $41.5 and an intraday high of $43.5997 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price. According to the SEC, on Jun 2, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 12,500 shares at $50.00 per share price. On May 26, 2016, Richard F Pops (director) sold 15,000 shares at $46.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.